Corticosteroids Market: Demographics, Safety Considerations, and the Move Toward Alternatives

The corticosteroids market was valued at USD 6.22 billion in 2025 and is projected to reach USD 9.35 billion by 2034, exhibiting a CAGR of 4.60% from 2026 to 2034. Demand is supported by demographic and healthcare trends, including rising global healthcare expenditure and a growing burden of chronic diseases, while safety concerns and new alternatives are reshaping how companies position their portfolios.

Aging Population Expands Demand

The report identifies the rising aging population as a key growth driver. As demographics skew toward older age groups, conditions such as osteoarthritis, rheumatoid arthritis, and chronic obstructive pulmonary disease (COPD) escalate, amplifying demand for corticosteroids used to manage inflammatory and degenerative disorders in the elderly. Rising global healthcare expenditure also broadens access to corticosteroid treatments for inflammatory and autoimmune disorders, supported by technological advancements, heightened patient awareness, and the growing burden of chronic diseases. With a growing need for musculoskeletal and respiratory care, the aging population is driving heightened usage. Corticosteroids are known for versatile applications and play pivotal roles in treatment regimens, and ongoing investments in healthcare infrastructure and research support improved patient access.

Adverse Reactions Remain a Constraint

The leading restraint is adverse reactions linked to prolonged or high-dose use, which the report lists as weight gain, osteoporosis, mood changes, and heightened infection susceptibility. Despite their therapeutic efficacy, these issues arise with prolonged or high-dose use. These concerns affect patient adherence and prompt healthcare providers to explore alternative treatments. Balancing the risk-benefit profile is crucial, especially in chronic conditions, to optimize use in managing inflammatory and autoimmune disorders while minimizing associated drawbacks.

Steroid-Sparing Therapies Gain Attention

The report tracks recent FDA novel approvals positioned around corticosteroid use. Anzupgo (delgocitinib) is a non-steroidal topical cream for moderate-to-severe chronic hand eczema where topical corticosteroids are inadequate, which highlights the need for steroid-sparing therapies. Wayrilz (rilzabrutinib) is an oral BTK inhibitor for persistent or chronic immune thrombocytopenia unresponsive to corticosteroids, and Tavneos (avacopan) is used alongside standard glucocorticoid treatment in ANCA-associated vasculitis to reduce steroid doses.

Sanofi's immunology pipeline shows a similar emphasis on reducing steroid use. The report describes Dupixent as a subcutaneous biologic that reduces the need for oral or topical corticosteroids in inflammatory skin and gut diseases. Its Phase 3 candidates include Dupixent (dupilumab) for ulcerative colitis, plus chronic spontaneous urticaria and bullous pemphigoid in certain regions; itepekimab for chronic rhinosinusitis without nasal polyps and COPD; lunsekimig for high-risk asthma, CRSwNP, atopic dermatitis, and COPD; amlitelimab for atopic dermatitis, asthma, and alopecia areata; and rilzabrutinib for chronic spontaneous urticaria and asthma. The report positions these candidates as aimed at reducing or minimizing corticosteroid use.

For atopic dermatitis, Eli Lilly reported in April 2022 that lebrikizumab combined with topical corticosteroids produced substantial improvement in disease severity. In the ADhere trial, which paired lebrikizumab with standard-of-care topical corticosteroids, 70% of patients with moderate-to-severe atopic dermatitis achieved at least a 75% improvement in overall disease severity (EASI-75) after 16 weeks.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/corticosteroids-market 

Regional Outlook and Key Players

North America captured approximately 37.92% of total revenue in 2025, helped by advanced healthcare infrastructure and high prescription volumes, while Asia-Pacific is likely to see significant growth. The region's landscape is tailored to region-specific medical conditions, with growth fueled by rising healthcare expenditure, increasing prevalence of those conditions, and government initiatives.

Key players include AbbVie Inc.; Astellas Pharma Inc.; AstraZeneca plc; Bausch Health Companies Inc.; Bayer AG; Cipla Limited; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Johnson & Johnson; Lupin Limited; Merck & Co., Inc.; Novartis International AG; Pfizer Inc.; and Sanofi S.A..

For B2B stakeholders, the report suggests that portfolio planning should account for both steady demand in established indications and a growing pipeline of alternatives that seek to lower reliance on corticosteroids in some conditions.

Conclusion

The Corticosteroids Market is expected to maintain steady growth due to the widespread use of corticosteroid medications in managing inflammatory, autoimmune, allergic, and respiratory conditions. Increasing prevalence of chronic inflammatory disorders and growing demand for effective treatment options are supporting market expansion. Advancements in drug delivery systems and pharmaceutical formulations are improving therapeutic applications. Expanding healthcare accessibility and continued pharmaceutical research are also contributing to industry development. However, concerns regarding adverse effects associated with prolonged corticosteroid use and the availability of alternative therapies may influence demand. The market is anticipated to remain an essential component of treatment strategies across multiple medical specialties.

More Trending Latest Reports By Polaris Market Research:

Rabies Veterinary Vaccine Market

APAC Pipeline Pigging Market

Wound Care Market

T4 DNA Ligase Market

APAC Pipeline Pigging Market

Muscle Stimulator Market

legal Marijuana Market

Angiogenesis Inhibitors & Stimulators: The Battle of Blood Vessels

Green and Bio Polyols Market